САРАТОН КАСАЛЛИГИНИ ЭРТА АНИҚЛАШ ВА БИОМАРКЕРЛАРДАН ФОЙДАЛАНИШ, МУАММОЛАР ВА ИМКОНИЯТЛАР ТАҲЛИЛИ
Abstract
Саратон касалликлари дунё миқёсида ўлим даражаси юқори бўлган хасталиклар қаторига киради. Уларни эрта босқичда аниқлаш, муваффақиятли даволаш имкониятини оширади ва беморларнинг умр давомийлигини узайтиради.
References
1. World Health Organization. (2022). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer
2. National Cancer Institute. (2021). Biomarkers in Cancer Research. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/biomarkers-fact-sheet
3. MedlinePlus. (2021). Cancer Screening and Early Detection. https://medlineplus.gov/cancerscreening.html
4. Sullivan, M. D., & Carson, J. P. (2018). Rehabilitation After Myocardial Infarction. Journal of Cardiac Rehabilitation, 32(5), 45-56.
5. Kenjayev Y.M., Berdieva S.A. (2024). Yurak bo‘lmacha va qorinchalari gipertrofiyasining elektrokardiografik belgilari. Termiz iqtisodiyot va servis universiteti.
6. World Health Organization (2022). Cancer Fact Sheet. https://www.who.int
7. GLOBOCAN (2020). Global Cancer Observatory. International Agency for Research on Cancer (IARC).
8. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
9. National Cancer Institute (2021). Cancer Causes and Risk Factors. https://www.cancer.gov
10. Siegel RL, Miller KD, Wagle NS, Jemal A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.
11. Kourou K, Yexarchos TP, Yexarchos KP, Karamouzis MV, Fotiadis DI. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8–17.
12. Jacobs IJ, Menon U, Ryan A, et al. (1993). Screening for ovarian cancer: CA 125 and pelvic ultrasonography. Lancet, 342(8877), 1240–1246.
13. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8–17.
14. Moore RG, McMeekin DS, Brown AK, et al. (2018). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 108(2), 402–408.
15. National Cancer Institute. (2021). Biomarkers in Cancer Research. https://www.cancer.gov/about-cancer/diagnosis-staging/biomarkers-fact-sheet
16. NCCN Clinical Practice Guidelines in Oncology. (2021). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2021.
17. Schröder FH, Hugosson J, Roobol MJ, et al. (2009). Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine, 360(13), 1320–1328.
